Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Matza, Louis S.; Stewart, Katie D.; Paczkowski, Rosirene; Coyne, Karin S.; Currie, Brooke; Boye, Kristina S.

doi:10.1186/s41687-018-0064-3

Journal of Patient-Reported Outcomes

Table 1 Demographic and Clinical Characteristics

From: Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Characteristic	Total Sample (N = 142)	Retest Sample (N = 42)
Age (mean, SD)	63.0 (9.8)	65.1 (8.4)
Gender (n, %)
Male	62 (43.7%)	19 (45.2%)
Female	80 (56.3%)	23 (54.8%)
Ethnic background (n, %)
Hispanic or Latino	4 (2.8%)	2 (4.8%)
Not Hispanic or Latino	138 (97.2%)	40 (95.2%)
Racial background (n, %)
Asian	12 (8.5%)	2 (4.8%)
Black	22 (15.5%)	6 (14.3%)
Caucasian	107 (75.4%)	32 (76.2%)
Other^a	7 (4.9%)	3 (7.1%)
Marital status (n, %)
Single	11 (7.7%)	3 (7.1%)
Married/Living with partner	98 (69.0%)	30 (71.4%)
Other^b	33 (23.2%)	9 (21.4%)
Employment status (n, %)^c
Full-time work	49 (34.5%)	15 (35.7%)
Part-time work	7 (4.9%)	1 (2.4%)
Other^d	86 (60.6%)	26 (61.9%)
Education level (n, %)
University degree or more	70 (49.3%)	20 (47.6%)
No university degree	72 (50.7)	22 (52.4%)
Current medication (n, %)^f
Non-insulin injectable medication^g	142 (100.0%)	42 (100.0%)
Exenatide extended release pen	26 (18.3%)	8 (19.0%)
Exenatide extended release tray	12 (8.5%)	1 (2.4%)
Exenatide	13 (9.2%)	4 (9.5%)
Pramlintide	2 (1.4%)	1 (2.4%)
Albiglutide	14 (9.9%)	5 (11.9%)
Dulaglutide	38 (26.8%)	15 (35.7%)
Liraglutide	38 (26.8%)	8 (19.0%)
Oral medication	104 (73.2%)	30 (71.4%)
Blimepiride	16 (11.3%)	6 (14.3%)
Glipizide	13 (9.2%)	3 (7.1%)
Canagliflozin	9 (6.3%)	3 (7.1%)
Metformin	83 (58.5%)	24 (57.1%)
Other	29 (20.4%)	9 (21.4%)
Insulin	58 (40.8%)	18 (42.9%)
Insulin lispro	8 (5.6%)	4 (9.5%)
Insulin detemir	16 (11.3%)	3 (7.1%)
Insulin aspart	8 (5.6%)	3 (7.1%)
Insulin glargine	27 (19.0%)	7 (16.7%)
Other^h	13 (9.2%)	6 (14.3%)

^a Other racial background includes for total sample includes American Indian (n = 2), Euro-American (n = 1), European (n = 1), Hawaiian (n = 2), Pacific Islander (Hawaiian) (n = 1). Other racial background for retest sample includes American Indian (n = 1), Euro-American (n = 1), and Pacific Islander (Hawaiian) (n = 1)
^b Other marital status for total sample includes divorced (n = 15), separated (n = 3), widowed (n = 14), and life partner (n = 1). Other marital status for retest sample includes divorced (n = 4), separated (n = 2)
^c Not mutually exclusive
^d Other for total sample includes employment status includes homemaker/housewife (n = 11), student (n = 2), unemployed (n = 4), retired (n = 80), disabled (n = 9), self-employed (n = 2); self-employed entrepreneur (n = 1); work from home (n = 1). Other for retest sample includes self-employed (n = 1)
5 Other education status for per protocol sample includes associates degree (n = 3), J.D. (n = 1), R.T license (n = 1), vocational degree – law enforcement certification (n = 1)
^e Participants were permitted to list multiple current medications and multiple discontinued medications. Therefore, the sub-rows do not necessarily add to the bolded total rows
^f One participant (ID 122–068) reported currently taking two non-insulin injectable medications for treatment of type 2 diabetes (pramlintide and exenatide extended release tray). When completing the DID-EQ, the participant rated pramlintide. When completing the DID-PQ, the participant compared pramlintide (Device 1) and exenatide extended release tray (Device 2)
^g Other for total sample includes: pioglitazone (n = 5); dapagliflozin (n = 5); empagliflozin (n = 5); sitagliptin and metformin (n = 4); sitagliptin (n = 3); repaglinide (n = 2); nateglinide (n = 2); glyburide (n = 1); saxagliptin (n = 1); linagliptin (n = 1). Other for retest sample includes: dapaglifozin (n = 2); empagliflozin (n = 2); nateglinide (n = 2); sitagliptin and metformin (n = 1); sitagliptin (n = 1); repaglinide (n = 1)
^h Other for total sample includes: Unspecified insulin (n = 5); insulin degludec (n = 3); human insulin (n = 2); insulin glargine (n = 2); insulin glulisine (n = 1). Other for retest sample includes: insulin unspecified (n = 3); human insulin (n = 1); insulin glulisine (n = 1); insulin degludec (n = 1)

Back to article page